Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa The stock price opened 20% higher on Wall Street after the Israeli company announced positive results from the phase 2 clinical trial of Docavitog, which it is developing with Sanofi, to treat ulcerative colitis (UC) and Crohn’s disease (CD).
Teva reported that the trial achieved preliminary results in ulcerative colitis and Crohn’s disease, the most common form of inflammatory bowel disease. According to the company’s announcement, the primary endpoint results in ulcerative colitis and Crohn’s disease for high doses represent the highest achieved with any TL1A monoclonal antibody.
Accordingly, Teva and Sanofi plan to begin the third phase of development for a treatment for inflammatory bowel disease (IBD), which is characterized by chronic inflammation of the digestive system and an estimated 10 million people around the world suffer from this condition.
“The results of the RELIEVE UCCD study have exceeded our expectations, and I am deeply impressed by the potential of duvakitug to help meaningfully treat and improve the quality of life of people living with these diseases,” said Eric Hughes, Head of Global R&D at Teva. “These positive results reinforce Teva’s ability to “Developing and accelerating access to innovative medicines. We are excited to collaborate on the next stage of development with our partner, Sanofi, and would like to thank the researchers and patients who participated in this study.”
Homan Ashrafian, Executive Vice President and Head of R&D at Sanofi, added: “These unprecedented results show that Dovacitog could represent the next frontier in the treatment of ulcerative colitis and Crohn’s disease. If the magnitude of effect continues in the Phase 3 program, we believe we will have a drug.” “The duvakitug program and this partnership underscore Sanofi’s strategy of following science to quickly identify and develop breakthrough medicines for patients.”
Teva’s stock price has risen by 58% since the beginning of the year
In the study, 36.2% (low-dose) and 47.8% (high-dose) of patients with ulcerative colitis treated with dovacetog achieved clinical remission compared with 20.45% who took placebo, and the placebo-adjusted rates were 15.7% (low-dose ) and 27.4%. (High dose). In patients with MS, 26.1% (low-dose) and 47.8% (high-dose) treated with Duvakitog achieved an endoscopic response compared with 13% who received placebo, and the placebo-adjusted rates were 13.0% (low-dose) and 34.8% (high dose). ), at week 14. Overall, the treatment effect was consistent across subgroups. This is the first and only randomized, placebo-controlled study to evaluate the effect of an anti-TL1A monoclonal antibody in CD. Detailed results are expected to be presented at a scientific forum in 2025.
Related articles
Teva partners with Sanofi to treat IBD
Teva withdraws from Japanese joint venture with Takeda
Can Teva keep its comeback?
Teva reports seventh straight quarter of growth
TL1A was developed by Teva, which last year signed an agreement with Sanofi to jointly develop the drug and received an initial payment of $500 million. Subject to achieving certain product development and launch milestones, Teva will receive additional payments. The companies will split the development costs and profits from the drug equally when it reaches the market.
Teva’s share price has risen 58% since the beginning of the year but has seen a decline somewhat recently before the trial results were published earlier today.
Published by Globes, Israel Business News – en.globes.co.il – on December 17, 2024.
© Copyright Globes Publisher Itonut (1983) Ltd., 2024.